Skip to content
Our šŸŽÆ Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

  • Post published:February 20, 2026
  • Post category:Analysis/News/Pα+
Read more about the article Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts

Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts

  • Post published:February 19, 2026
  • Post category:Analysis
Read more about the article Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

  • Post published:February 17, 2026
  • Post category:Analysis/News/Pα+
Read more about the article BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

  • Post published:February 17, 2026
  • Post category:Analysis/News/Pα+
Read more about the article Q4’25 Psychedelic Lobbying Update

Q4’25 Psychedelic Lobbying Update

  • Post published:February 13, 2026
  • Post category:Analysis/News/Pα+
Read more about the article Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

  • Post published:February 5, 2026
  • Post category:Analysis/Interviews/News
Read more about the article Q3 2025: Oregon Psilocybin Services Update

Q3 2025: Oregon Psilocybin Services Update

  • Post published:February 2, 2026
  • Post category:Analysis/News/Pα+
Read more about the article January 2026 Psychedelic Bill Round-up

January 2026 Psychedelic Bill Round-up

  • Post published:January 30, 2026
  • Post category:Analysis/Pα+
Read more about the article Psychedelic Funding, Public Markets, and M&A in 2025

Psychedelic Funding, Public Markets, and M&A in 2025

  • Post published:January 20, 2026
  • Post category:2025 Year in Review/Analysis/Pα+
Read more about the article Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

  • Post published:January 15, 2026
  • Post category:2025 Year in Review/Analysis/News/Pα+

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha Ā© 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More